2014
HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment – a study protocol for a cluster randomised trial
Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, Bock P, Griffith S, Moore A, Watson-Jones D, Fraser C, Vermund SH, Fidler S, The HPTN 071 (PopART) Study Team. HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment – a study protocol for a cluster randomised trial. Trials 2014, 15: 57. PMID: 24524229, PMCID: PMC3929317, DOI: 10.1186/1745-6215-15-57.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnti-HIV AgentsCircumcision, MaleClinical ProtocolsCost-Benefit AnalysisDrug Administration ScheduleFemaleHealth Care CostsHIV InfectionsHumansIncidenceMaleMass ScreeningPredictive Value of TestsPrevalenceResearch DesignSouth AfricaTime FactorsTreatment OutcomeYoung AdultZambiaConceptsImmediate antiretroviral treatmentAntiretroviral treatmentHIV incidenceHIV testingCombination HIV prevention packageHIV combination prevention interventionsHome-based HIV testingUniversal testingCombination prevention interventionsHIV prevention packageHPTN 071 (PopART) trialUniversal HIV testingHIV-negative menCluster-randomised trialCurrent national guidelinesStandard of careMedical male circumcisionPublic health problemThree-arm designPotential adverse effectsART initiationHPTN 071Testing HIVSecondary outcomesArm B
2013
Optimizing PMTCT service delivery in rural North-Central Nigeria: Protocol and design for a cluster randomized study
Aliyu MH, Blevins M, Audet C, Shepherd BE, Hassan A, Onwujekwe O, Gebi UI, Kalish M, Lindegren ML, Vermund SH, Wester CW. Optimizing PMTCT service delivery in rural North-Central Nigeria: Protocol and design for a cluster randomized study. Contemporary Clinical Trials 2013, 36: 187-197. PMID: 23816493, PMCID: PMC3786261, DOI: 10.1016/j.cct.2013.06.013.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsCD4 Lymphocyte CountCost-Benefit AnalysisFamilyFemaleHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalMaternal-Child Health CentersMentorsNigeriaPatient SatisfactionPoint-of-Care SystemsPregnancyPrenatal CareResearch DesignRural PopulationSocioeconomic FactorsConceptsAntiretroviral therapyPMTCT servicesChild transmissionHIV service integrationPMTCT service deliveryPMTCT service provisionChild HIV transmissionPrevention of motherCell count testingSimilar resource-limited settingsRural health facilitiesRural North-Central NigeriaResource-limited settingsPatient care responsibilitiesPMTCT careMore HIVHIV infectionCare CD4Cell count resultsHIV transmissionPregnant womenUNAIDS/Health facilitiesHealth providersInfluential community members
2012
Cervical Cancer Prevention in Low- and Middle-Income Countries: Feasible, Affordable, Essential
Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH. Cervical Cancer Prevention in Low- and Middle-Income Countries: Feasible, Affordable, Essential. Cancer Prevention Research 2012, 5: 11-17. PMID: 22158053, PMCID: PMC3586242, DOI: 10.1158/1940-6207.capr-11-0540.Peer-Reviewed Original ResearchConceptsCervical cancer preventionHuman immunodeficiency virusCervical cancerMiddle-income countriesCancer preventionPrevention servicesCervical cancer prevention servicesCancer prevention servicesCervical cancer screeningGynecologic issuesImmunodeficiency virusHuman papillomavirusCancer screeningEarly treatmentPelvic examHigh-income countriesWorldwide burdenCare deliveryNew casesScreening testHPVCancerLMICsEffective alternativePrevention
2003
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia
Stringer EM, Sinkala M, Stringer J, Mzyece E, Makuka I, Goldenberg RL, Kwape P, Chilufya M, Vermund SH. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 2003, 17: 1377-1382. PMID: 12799559, PMCID: PMC2745990, DOI: 10.1097/00002030-200306130-00012.Peer-Reviewed Original ResearchConceptsPrevention of motherResource-limited settingsHIV infectionVoluntary counselingChild HIV transmissionPerinatal HIV infectionHIV prevention programsNVP therapyChild transmissionPatient attritionHIV transmissionPregnant womenPrevention programsNevirapineHIVHealth employeesThousands of womenTransmission routesLusakaMothersInfectionPreventionWomenCounselingInfants
2000
Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A. Cost-Effective Use of Nevirapine to Prevent Vertical HIV Transmission in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 369-377. DOI: 10.1097/00042560-200008010-00012.Peer-Reviewed Original ResearchConceptsVertical HIV transmissionHIV transmissionPrenatal carePrevention strategiesEffects of NVPModest clinical efficacyOptimal prevention strategiesGreater health gainsDecision analysis modelNevirapine administrationNVP administrationPrenatal visitPreventive therapyStandard therapyClinical efficacySaharan AfricaMass therapyPrenatal strategiesClinical assessmentPrior enrollmentTherapyCost-effective useHealth gainsWomenSerostatusCost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
Stringer J, Rouse D, Vermund S, Goldenberg R, Sinkala M, Stinnett A. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 369-77. PMID: 11015154, DOI: 10.1097/00126334-200008010-00012.Peer-Reviewed Original ResearchConceptsVertical HIV transmissionHIV transmissionPrenatal carePrevention strategiesEffects of NVPModest clinical efficacyOptimal prevention strategiesSaharan AfricaGreater health gainsDecision analysis modelNevirapine administrationNVP administrationPrenatal visitPreventive therapyStandard therapyClinical efficacyMass therapyPrenatal strategiesClinical assessmentPrior enrollmentTherapyCost-effective useHealth gainsWomenSerostatus
1993
Decision making for clinical trials and prevention research: commentary on the model of Paltiel and Kaplan.
Vermund SH. Decision making for clinical trials and prevention research: commentary on the model of Paltiel and Kaplan. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1993, 6: 176-8. PMID: 8433282.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeClinical Trials as TopicCost-Benefit AnalysisDecision MakingDecision Support TechniquesHumansPolicy Making